NCT01486823

Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects

An Open-label, Single-dose Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: BioInvent International AB · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a study in healthy volunteers designed to investigate the PK following intravenous and subcutaneous administration of MLDL1278A (also known as BI-204). The bioavalialbility of MLDL1278A after subcutaneous administration will be determined.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	MLDL1278A	Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.
DRUG	MLDL1278A	Single subcutaneous dose of 360 mg MLDL1278A.

Timeline

• Start date: 2011-11-01
• Primary completion: 2012-07-01
• Completion: 2012-07-01
• First posted: 2011-12-07
• Last updated: 2012-12-11

Locations

1 site across 1 country: United Kingdom